Stock comparison
Arbutus Biopharma
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABUS
Arbutus Biopharma
Market cap
$859.29M
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABUS | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 49D | 69B | MTD |
| Benjamin Graham | 43D | 65B | MTD |
| Philip Fisher | 55C | 63C | MTD |
| Peter Lynch | 48D | 66B | MTD |
| Joel Greenblatt | 100A | 68B | ABUS |
| Charlie Munger | 64D | 74B | MTD |
| Terry Smith | 66B | 70B | MTD |
Side-by-side metrics
| Metric | ABUS | MTD |
|---|---|---|
| Market cap | $859.29M | $22.29B |
| P/E (TTM) | 5.1x | 25.3x |
| EV/EBIT | - | 21.6x |
| ROIC (TTM) | 56.72% | 36.09% |
| Gross margin | 99.98% | 57.79% |
| Net margin | 83.95% | 21.4% |
| Revenue CAGR 5y | 6.4% | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | 0.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABUS leads on
- EV/EBIT-vs 21.6x+173%
- P/E (TTM)5.1xvs 25.3x+80%
- Net margin83.95%vs 21.4%+75%
- Revenue CAGR 5y6.4%vs 2.01%+69%
MTD leads on
- Debt / Equity-vs 0.0x+100%
- Market cap$22.29Bvs $859.29M+96%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.